|
ValiRx PLC on Monday said subsidiary Inaphaea BioLabs has agreed an exclusive licensing deal with Dominion Biotech Ltd for Inaphaea’s PredictRx platform. ValiRx is an Essex-based life sciences company focusing on early-stage cancer therapeutics and women’s health. Inaphaea is a Nottingham-based contract research firm also specialising in oncology and women’s health, wholly-owned by ValiRx, and Dominion is a Manchester-based provider of patient-derived cell models and assays to pharmaceutical companies. Under the terms of the agreement, Inaphaea will receive a 50% share of the net revenues from Dominion’s offering of PredictRx. Dominion and Inaphaea will also share ownership of any new patient-derived cells developed. PredictRx is a personalised cancer screening service in which a patient’s tumour sample is processed into patient-derived cells, and then subjected to a drug combination screening panel to determine the most appropriate chemotherapy treatment protocols. ‘We have expanded our relationship with Dominion as we continue to develop and commercialise Inaphaea’s asset base,’ said ValiRx Chief Executive Officer Mark Eccleston. ‘PredictRx is a pioneering, in-vitro approach for predicting drug sensitivity for cancer therapies at the individual patient level based on analysis of the patient’s own cancer cells. This can deliver significant benefit by identifying the most effective treatment options leading to a truly personalised approach to therapy which ultimately should deliver improved outcomes for patients. ‘Inaphaea’s focus is translational drug development services and monetising of its biobank through its PDC models and through this license to Dominion which will develop and commercialise the PredictRx clinical service globally.’ The deal carries an initial two-year period followed by annual options for renewal. Either company can initiate a buyout of the other’s rights after 18 months under pre-agreed terms ‘based on a multiple of trailing net revenue’, ValiRx explained. ValiRx anticipates ‘modest’ initial revenues, but noted the agreement is ‘strategically important in demonstrating the commercial application of ValiRx’s platform and establishing future buyout value’. Shares in ValiRx were down 7.5% at 0.56 pence in London on Monday afternoon. The stock is down 79% over the past year. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
